BioPorto A/S (BIOPOR.CO)
| Previous close | 2.4850 |
| Open | 2.4850 |
| Bid | 2.4100 x 0 |
| Ask | 2.4300 x 0 |
| Day's range | 2.4100 - 2.4900 |
| 52-week range | 2.3500 - 7.3600 |
| Volume | |
| Avg. volume | 502,768 |
| Market cap | 650.642M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 12 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
- Globe Newswire
Grant of warrants
December 31, 2021Announcement no. 24Grant of warrants Today, the Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR) has exercised its current authorization by issuing 12,600,000 warrants to key employees and executive management of BioPorto. The warrants are issued in accordance with the company’s remuneration policy and the authorization in section 17 a of the Articles of Association. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise pri
- Globe Newswire
Pipeline Update on gRAD Tests
December 31, 2021News release Pipeline Update on gRAD Tests BioPorto A/S (BioPorto) is supporting Rigshospitalet (RH), Copenhagen, with quantitative thrombomodulin tests based on its generic Rapid Assay Device (gRAD) technology. RH is investigating the potential for thrombomodulin blood levels to be used as a marker in patients with sepsis to indicate who could benefit from treatment with the drug prostacyclin. RH is currently summarizing findings from its feasibility study and plans to publish
- Globe Newswire
In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients
November 19, 2021Announcement no. 23 In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients In July 2021, BioPorto A/S (BioPorto) initiated a dialogue with the US Food and Drug Administration (FDA) on a potential Emergency Use Authorization (EUA) of an NGAL assay for use in predicting the need for renal replacement therapy in COVID-19 patients. Th
